Diagnostic values, association with disease activity and possible risk factors of anti-PAD4 in rheumatoid arthritis: a meta-analysis
Authors' conclusion
Our study suggests that anti-PAD4 antibody is a potentially useful diagnostic biomarker and clinical indicator for RA.
Study context
- Population
- Patients with RA; studies from five databases up to 1 December 202224 journal articles and one letter
- Comparison
- Anti-PAD4-positive vs anti-PAD4-negative RA; RA vs healthy individuals and other rheumatic diseases
- Outcome
- Diagnostic value of anti-PAD4 antibody in RA
Methodological detailsbivariate mixed-effect models, summary receiver operating characteristics (SROC) curve, QUADAS-2, random-effects model
- Bivariate mixed-effect models
- SROC curve
- QUADAS-2
- Random-effects model
Pooled result
As reported in the abstract
Diagnostic value of anti-PAD4
- Good diagnostic value between RA and healthy individuals
- Possibly lower diagnostic value between RA and other rheumatic diseases
- Slightly enhanced RA diagnostic sensitivity combined with ACPA or ACPA/RF
Further pooled results
Risk factors for anti-PAD4
- Positively correlated with HLA-SE
- Negatively correlated with ever or current smoking
Disease activity and clinical features
- Anti-PAD4-positive RA had higher DAS28, ESR, swollen joint count (SJC) and possibility of interstitial lung disease (ILD) and pulmonary fibrosis vs those without
Original publication
Diagnostic values, association with disease activity and possible risk factors of anti-PAD4 in rheumatoid arthritis: a meta-analysis. Rheumatology (Oxford). Published 12 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →